Новые возможности улучшения прогноза больных хронической ишемической болезнью сердца

Standard

Новые возможности улучшения прогноза больных хронической ишемической болезнью сердца. / Perepech, Nikita B.

в: Rational Pharmacotherapy in Cardiology, Том 15, № 6, 2019, стр. 873-880.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

BibTeX

@article{77ce86b7d2f54062b90ba76083c32c7c,

title = "Новые возможности улучшения прогноза больных хронической ишемической болезнью сердца",

abstract = "Resources and methods for improving the prognosis in patients with chronic ischemic heart disease (IHD) are presented in the review. Information on the classes of drugs that improve the prognosis, and target values of the main physiological parameters that should be monitored during the treatment of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents and anticoagulants. The results of the most significant randomized clinical trials of the efficacy and safety of drugs from these classes in the treatment of chronic IHD are discussed. The results of the COMPASS study, which obtained confirmation of the positive effect of combined therapy with rivaroxaban and acetylsalicylic acid on the prognosis of patients with chronic IHD or peripheral artery disease, are presented in detail. The safety aspects of this therapy are discussed. The position of rivaroxaban in the treatment of patients with chronic IHD with sinus rhythm is presented according to the Recommendations of the European Society of Cardiology for the diagnosis and treatment of chronic IHD (2019).",

keywords = "Antiplatelet agents, Chronic ischemic heart disease, Efficacy and safety of therapy, Prognosis, Rivaroxaban",

author = "Perepech, {Nikita B.}",

year = "2019",

doi = "10.20996/1819-6446-2019-15-6-873-880",

language = "русский",

volume = "15",

pages = "873--880",

journal = "Rational Pharmacotherapy in Cardiology",

issn = "1819-6446",

publisher = "Столичная издательская компания",

number = "6",

}

RIS

TY - JOUR

T1 - Новые возможности улучшения прогноза больных хронической ишемической болезнью сердца

AU - Perepech, Nikita B.

PY - 2019

Y1 - 2019

N2 - Resources and methods for improving the prognosis in patients with chronic ischemic heart disease (IHD) are presented in the review. Information on the classes of drugs that improve the prognosis, and target values of the main physiological parameters that should be monitored during the treatment of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents and anticoagulants. The results of the most significant randomized clinical trials of the efficacy and safety of drugs from these classes in the treatment of chronic IHD are discussed. The results of the COMPASS study, which obtained confirmation of the positive effect of combined therapy with rivaroxaban and acetylsalicylic acid on the prognosis of patients with chronic IHD or peripheral artery disease, are presented in detail. The safety aspects of this therapy are discussed. The position of rivaroxaban in the treatment of patients with chronic IHD with sinus rhythm is presented according to the Recommendations of the European Society of Cardiology for the diagnosis and treatment of chronic IHD (2019).

AB - Resources and methods for improving the prognosis in patients with chronic ischemic heart disease (IHD) are presented in the review. Information on the classes of drugs that improve the prognosis, and target values of the main physiological parameters that should be monitored during the treatment of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents and anticoagulants. The results of the most significant randomized clinical trials of the efficacy and safety of drugs from these classes in the treatment of chronic IHD are discussed. The results of the COMPASS study, which obtained confirmation of the positive effect of combined therapy with rivaroxaban and acetylsalicylic acid on the prognosis of patients with chronic IHD or peripheral artery disease, are presented in detail. The safety aspects of this therapy are discussed. The position of rivaroxaban in the treatment of patients with chronic IHD with sinus rhythm is presented according to the Recommendations of the European Society of Cardiology for the diagnosis and treatment of chronic IHD (2019).

KW - Antiplatelet agents

KW - Chronic ischemic heart disease

KW - Efficacy and safety of therapy

KW - Prognosis

KW - Rivaroxaban

UR - http://www.scopus.com/inward/record.url?scp=85079684035&partnerID=8YFLogxK

U2 - 10.20996/1819-6446-2019-15-6-873-880

DO - 10.20996/1819-6446-2019-15-6-873-880

M3 - статья

AN - SCOPUS:85079684035

VL - 15

SP - 873

EP - 880

JO - Rational Pharmacotherapy in Cardiology

JF - Rational Pharmacotherapy in Cardiology

SN - 1819-6446

IS - 6

ER -

ID: 74574232